Although hyperkinesis is expressed in several neurological disorders, the biological basis of this phenotype is unknown. The mouse mutant coloboma (Cm/+) exhibits profound spontaneous locomotor hyperactivity resulting from a deletion mutation. This deletion encompasses several genes including Snap, which encodes SNAP-25, a nerve terminal protein involved in neurotransmitter release. Administration of amphetamine, a drug that acts presynaptically, markedly reduced the locomotor activity in coloboma mice but increased the activity of control mice implicating presynaptic function in the behavioral abnormality. In contrast, the psychostimulant methylphenidate increased locomotor activity in both coloboma and control mice. When a transgene encoding SNAP-25 was bred into the coloboma strain to complement the Snap deletion, the hyperactivity expressed by these mice was rescued, returning these corrected mice to normal levels of locomotor activity. These results demonstrate that the hyperactivity exhibited by these mice is the result of abnormalities in presynaptic function specifically attributable to deficits in SNAP-25 expression.
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Key words: hyperactivity; ADHD; locomotor activity; amphetamine; methylphenidate; transgenic; SNAP-25; mouse mutant; psychostimulant; coloboma Pathological hyperactivity is a common problem in pediatric neuropsychiatry. Hyperactivity syndromes are thought to account for a large proportion of children diagnosed with learning disabilities, and are extremely disruptive to families and school environments. Therefore, a great deal of attention has been focused on the causes and treatment of hyperactivity in children. It is almost certain that multiple factors, both genetic and environmental, contribute to the development of hyperactivity. This observation is supported by the fact that pathological hyperactivity exists as a major feature of several distinct neuropsychiatric syndromes. For example, attention deficit-hyperactivity disorder (ADHD) is described by poor attention span, impulsivity, hyperactive behavior, and it is the most common pediatric neuropsychiatric disorder, affecting -2-4% of school age children (Whalen and Henker, 1976; Shaywitz and Shaywitz, 1984; Anastopoulos and Barkley, 1988; Safer and Krager, 1988) . Tourette syndrome is another childhood onset disorder, characterized by vocal and motor tics, in which hyperactivity is a comorbid condition in -50% of affected individuals (Pauls et al., 1986) . Although hyperactivity is a cardinal sign in many neurological disorders, the lack of a genetically defined animal model of hyperkinesis has hampered efforts to identify the biological deficits underlying this behavioral phenotype.
We have recently identified the mouse mutant coloboma as a novel animal model for examining the neurobiological basis of hyperactivity (Hess et al., 1992) . Mice heterozygous for the semidominant mutation coloboma (Cm) exhibit a triad of overt abnormalities consisting of profound spontaneous hyperactivity, head bobbing, and ocular dysmorphology (Searle, 1966; Hess et al., 1992) . The hyperactivity exhibited by coloboma mice averages 3 times the activity of the control littermates. In fact, the activity of some mutants exceeds 10 times that of their control littermates. Although the spontaneous hyperactivity is extreme, the coloboma mouse CNS appears normal with no obvious neuropathology.
We have previously defined the genetic defect in these mice as a deletion mutation on mouse chromosome 2 comprised of l-2 CM encompassing genes encoding phospholipase C isoform p-1 and the nerve terminal protein SNAP-25 (Hess et al., 1992 , 1994 . Recent evidence suggests that SNAP-25, which is associated with the plasma membrane of axon terminals (Oyler et al., 1989) , plays a critical role in neurotransmitter release in the nervous system. SNAP-25 has been identified as a component of the machinery essential for docking and holding synaptic vesicles at the presynaptic membrane in readiness for Ca"'-triggered neurotransmitter exocytosis (Horikawa et al., 1993; O'Connor et al., 1993; Sollner et al., 1993a,b) . That neurotransmission is blocked by botulinum neurotoxins A and E, which specifically recognize and cleave SNAP-25, provides additional evidence for the involvement of SNAP-25 in vesicle fusion (Blasi et al., 1993; Schiavo et al., 1993) . In coloboma (Cm/+) mice, deletion of the Snap gene results in 50% lower amounts of SNAP-25 mRNA and protein expression than wild-type (+/+) mice (Hess et al., 1992) . Because the intact Snap allele in Cm/+ mice does not compensate for the deleted Snap gene with increased transcription, it is likely that deficiencies in SNAP-25 expression, resulting in anomalous presynaptic function, are involved in the neurological abnormalities exhibited by these mutant mice. Here we demonstrate that the hyperactivity expressed by coloboma mice is clearly the result of a deletion of the Snap gene. 
MATERIALS AND METHODS

RESULTS
Amphetamine responses Amphetamine, a psychostimulant that acts at the presynaptic terminal to promote catecholamine release, is effective in ameliorating the hyperactivity expressed in ADHD-affected children (Barkley, 1977; Shaywitz and Shaywitz, 1984) . Coloboma mice were challenged with the indirect dopamine agonist amphetamine, and the behavioral response was assessed by evaluating spontaneous locomotor activity and stereotypic behavior. As shown in Figure 1 , coloboma mice were 3-4 times more active than normal littermates after saline administration throughout the 3 hr testing period. However, subcutaneous injection of d-amphetamine sulfate markedly suppressed coloboma mouse activity 20-90 min after injection. In the 20-90 min after injection, 2 mg/kg amphetamine significantly reduced the locomotor activity of coloboma mice compared with the locomotor activity exhibited by coloboma mice treated with saline (Student's t test, p < 0.05). After coloboma mice received 4 mg/kg amphetamine, a trend toward a reduction in locomotor activity below salinetreated baseline Cm/+ activity was also observed (Student's t test, p < 0.09). These doses either produced no effect (2 mg/kg) or potentiated locomotor activity (4 mgikg) in control mice.
Psychostimulants, such as amphetamine, can also induce repetitive, focused behaviors (stereotypy) that result in decreased locomotor activity. To distinguish between drug-induced stereotypy and a drug-induced reduction in locomotor activity without stereotypy, mice were observed and rated for their qualitative response to amphetamine for 120 min after injection. Consistent with the locomotor activity recorded by the photocell cages, the behavioral ratings demonstrated that saline-injected coloboma mice were significantly more active than their wild-type littermates (Fig. 2 ). Exposure to 2 or 4 mgikg d-amphetamine decreased the activity of CmJ+ mice between 20 and 90 min postinjection without inducing stereotypy. During this time, Cm/+ mice treated with amphetamine scored in the normal mouse activity range of l-2 (Fig. 2) .
Higher doses of amphetamine induced stereotypy in both control and coloboma mice. At 8 mgikg amphetamine, occasional bursts of stereotyped behavior were observed in mutant and wild-type mice. Although +/+ locomotor activity was clearly potentiated by this dose, coloboma mouse activity was still below baseline coloboma locomotor activity. At the highest dose of amphetamine administered, persistent stereotypy was observed in both control and coloboma mice. At all doses of amphetamine, the behavioral effects of the drug diminished in parallel with control and coloboma mice returning to baseline levels of activity, reflecting comparable drug clearance in normal and mutant mice.
Because the amphetamine-induced reduction in locomotor activity in coloboina mice was remarkably similar to the response of ADHD-affected children administered psychostimulants (Barkley, 1977; Shaywitz and Shaywitz, 1984) we also tested coloboma mice in the same behavioral paradigm with methylphenidate, the drug more commonly used to treat hyperactive children. The dose-dependent response to methylphenidate in coloboma mice was markedly different from the amphetamine response. Methylphenidate (2-32 mg/kg) increased the locomotor activity in both control and coloboma mice in a dose-dependent manner (Fig. 3) . Stereotypy was also induced in parallel in control and coloboma mice (data not shown); persistent stereotypy was only observed at the highest doses of methylphenidate (16 and 32 mg/kg). Thus, Data represent mean -C SEM. ANOVA for repeated measures indicated a significant repeated-measures effect for 4 mgikg methylphenidate (Fw,) = 18.514,~ < 0.0005) and 8 mgikg methylphenidate (F(,,,,) = 38.291, p < 0.0005) with no significant effects of groups or interaction for either dose. A significant Genotype X Time interaction effect was observed for 2 mgkg methylphenidate (Fc,7,238j = 2.164,~ < 0.01) and 32 mgkg methylphenidate (Fc17,238j = 5.409,~ < 0.0005).
unlike amphetamine, the methylphenidate response in coloboma mice appears normal.
Transgenic mice overexpressing SNAP-25
Because the abnormal response to amphetamine suggested a presynaptic component to the regulation of locomotor hyperactivity in coloboma mice, the contribution of reduced SNAP-25 expression to the coloboma phenotype was tested by generating transgenic mice overexpressing SNAP-25 to be crossed with Cmlimutants to compensate for the deleted Snap allele. For this rescue experiment, a SNAP-25 minigene (Sp) was constructed using 10 kb of genomic DNA 5' to and including the transcriptional start site of the Snap gene (Ryabinin et al., 1996) to drive expression. Preliminary experiments showed that this region upstream of the transcriptional start site was sufficient to drive P-galactosidase gene activity in PC12 cells (E. Hess and M. Wilson, unpublished data). The Snap gene encodes two isoforms of the protein, SNAP25a and SNAP-25b, which are generated by alternative splicing (Bark, 1993) . This Snap promoter was fused to the intact coding sequence corresponding to the SNAP-25b isoform, the predominant SNAP-25 mRNA species expressed in adult brain (Bark et al., 1995) . Post-transcriptional processing was provided by incorporating the short intron 1 of the rat insulin II gene into the 5'untranslated sequences of the SNAP-25 cDNA, and the SV40 polyadenylation sequence was added to the 3' end of the cDNA (Fig. 4) . Founder lines of transgenic mice generated with C3H/ HeJXC57B1/6 hybrid embryos were expanded and bred onto the C3H/HeJ strain, the strain on which the Cm mutation has been inbred. After breeding the transgene to homozygosity, several lines were identified that expressed the SNAP-25 transgene in brain. Mice either hemizygous or homozygous for the transgene exhibited no overt behavioral defects and were phenotypically indistinguishable from nontransgenic littermates.
Expression of the Snap transgene
The level of transgene expression in six founder lines was compared using in situ hybridization. To distinguish the expression of the transgene from endogenous SNAP-25 expression, an RNA probe to the SV40 polyadenylation sequence was used to detect the transgene transcript. The pattern of expression of the transgene in the CNS was similar in all founder lines with some variability in relative levels of expression. Although the transgene was expressed at somewhat lower levels than the endogenous gene, the Snap minigene was expressed throughout the brain, similar to endogenous SNAP-25 expression (Fig. 5) . No detectable hybridization was found in myelinated tracts or in gliaenriched regions of white matter, consistent with the neuronspecific expression of SNAP-25. For most lines, high levels of Snap transgene expression were present in granular layer of the cerebellum, and expression was also present in cortical and subcortical brain regions. Using an SV40 polyadenylation signal probe similar to that used for the in situ hybridization, RNase protection assays to tissue RNAs of the Snap minigene founder 40 line confirmed the expression of the transgene in cortex as well as higher levels in cerebellum, but notably also demonstrated lack of expression in non-neuronal tissue including liver, kidney, and spleen (data not shown). Additionally, SNAP-25 protein levels in brain were assessed in transgenic mice derived from founder line 40 using a monoclonal antibody (SMI81) to SNAP-25 in a quantitative slot blot analysis of brain extracts of coloboma mice without (genotype, -/-Cm/+) or homozygous for the transgene (genotype, Sp/Sp Cm/+), the genotype in which complete correction of the hyperactivity was observed (see below). For comparison, the level of SNAP-25 protein in nontransgenic, wild-type -I-+/+ mice was used as reference for "normal" levels of SNAP-25 protein expression. Although analysis of proteins extracted from whole brain demonstrated only a small (5%) increase in SNAP-25 protein expression in Sp/Sp Cm/+ over -/-Cm/+ mice, a regional analysis revealed a differential pattern of transgene-induced SNAP-25 protein expression in brain regions directly involved in the regulation of motor activity. In striatum and cerebellum of Cm/+ mice homozygous for the transgene SNAP-25, protein levels were increased by >30% compared with coloboma mutants (relative to normal -/--+/+ levels in striatum: Sp/Sp Cm/+ 0.812 + 0.090, -I-Cm/+, 0.613 t 0.007; in cerebellum: Sp/Sp Cm/+ 0.759 t 0.053, -I-Cm/+ 0.557 ? 0.004). In contrast to the apparent restoration to -80% of normal mouse SNAP-25 levels in these regions, SNAP-25 expression in cerebral cortex was comparable in Cm/+ mice with or without the transgene.
Transgenic rescue of hyperactivity in coloboma mice To determine the precise relationship of SNAP-25 to the coloboma phenotype, the Snap transgene was bred onto the coloboma mouse strain. The resulting mice were evaluated visually for head bobbing and ocular dysmorphology, and their locomotor activity was quantified. As shown in Figure 6 , +/+ mice without (-/-), or hemizygous (Sp/-) or homozygous (Sp/Sp) for the transgene exhibit virtually identical levels of activity, consistent with little or no obvious effect of the transgene on wild-type behavior. In contrast, the Cm/+ mice homozygous for the transgene (Sp/Sp Cm/+) were significantly less active than the nontransgenic Cm/+ littermates; in fact, Sp/Sp Cm/+ mice exhibited activity comparable with control littermates. Additionally, there was a trend toward a reduction in activity in Cm/+ mice hemizygous for the Snap minigene (Sp/-Cm/+), consistent with a dose response of the transgene complementing the hyperactivity resulting from the Cm deletion mutation.
Although the SNAP-25 transgene bred into the coloboma line clearly resulted in mice with quantitatively normal locomotor activity, expression of the transgene was not sufficient to completely rescue all elements of the coloboma phenotype. Mice homozygous for the transgene, for example, displayed more individual variability in their level of activity than nontransgenic and transgenic normal (+/+) animals. Head bobbing, which is seen in virtually all coloboma mice, was observed in 5 of the 6 Sp/Sp Cm/+ mice. Additionally, although we have observed that the severity of the eye dysmorphology in the mutants varies consid-
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Genotype F&ure 6. Complementation of spontaneous hyperactivity in coloboma mice by the Snap transgene (Sp). Progeny (n = 92) generated from an Spl-+I+ X Spl-Cm/+ cross were tested for spontaneous locomotor activity. Activity was recorded for 3 hr and is expressed as average movements per 10 min. Data represent mean Y? SEM. Data were analyzed by one-way ANOVA followed by a Scheffe's post hoc test. Asterisk indicates significantly different (p < 0.05) from -/-Cm/+ mice derived from the same cross. Note that the locomotor activity expressed by Sp/Sp Cm/+ mice was not significantly different from +/+ mice either with or without the transgene. All data presented were obtained from a single transgenic founder (line 40); similar results have been obtained from the progeny of the same cross matings with two additional founder lines (lines 4 and 45) wherein homozygosity for the transgene was also effective in significantly reducing the hyperactivity of Cm/+ mice.
erably, and is not always observed in all Cm/+ mice, 3 of the 6 Sp/Sp Cm/+ mice had the sunken, closed-eye characteristic of the coloboma phenotype, whereas 14 of 19 Sp/-Cm/+ mice and 8 of 10 -/-Cm/+ mice bore this dysmorphology.
Restoration of the amphetamine response The "rescued" Cm/+ mice were tested for their response to amphetamine to determine whether the amphetamine response was corrected in parallel with the transgene-induced reduction in locomotor activity. Although amphetamine significantly reduced the locomotor activity of nontransgenic Cm/+ mice, the same dose of amphetamine increased activity of Sp/Sp Cm/+ mice (Fig.  7) . The amphetamine-induced increase in activity was comparable with amphetamine responses in wild-type ( Fig. 1) and SplSp +/+ mice (Fig. 7) . Thus, the Snap transgene reversed the paradoxical suppressive effect of amphetamine attributed to the Cm mutation.
DISCUSSION
Coloboma mice represent an unprecedented model in which to study the contributions of a single known gene to a complex multifactorial phenotype in humans. The expression of SNAP-25, a presynaptic protein involved in synaptic vesicle fusion and transmitter release, is reduced in coloboma mice. Replacement of the deleted Snap gene with a Snap transgene ameliorated the hyperactivity, demonstrating that the reduction in SNAP-25 expression is sufficient to cause hyperactivity. In fact, the rescue of the hyperactivity was clearly dependent on the "dose" of transgene with the minigene in the hemizygous state reducing, but not eliminating, the hyperactivity. In the homozygous state, the transgene clearly provided enough SNAP-25 to complement the hyperactivity completely, although SNAP-25 expression did not achieve wild-type mRNA or protein levels. SNAP-25 is expressed as two isoforms in the CNS; in the mouse, SNAP-25a is the mRNA species associated with early CNS development and SNAP-25b is the major isoform expressed in adult brain (Bark et al., 1995) . The SNAP-25b cDNA was used in the transgene and effectively complemented the hyperactivity, suggesting that the hyperactivity is a consequence of persistent SNAP-25b deprivation in the adult coloboma mouse and not a result of developmental anomalies associated with a reduction in the SNAP-25a isoform. SNAl25b is thought to participate in docking and fusion of small, clear synaptic vesicles for neurotransmitter release (see Bark and Wilson, 1994; Bark et al., 1995) . Consequently, as a structural element of regulated vesicle fusion, the reduced level of SNAP-25b expression likely results in deficits in the efficiency of neurotransmitter release that are ultimately expressed phenotypically as hyperactivity. Because hyperactivity is observed with 50% levels of SNAP-25 protein in Cm/+ mice, the behavioral phenotype may represent those pathways placing a high demand on SNAP-25 function. In fact, the striatum and cerebellum, regions implicated in locomotor activity, achieved near normal levels of SNAP-25 expression in rescued mice, suggesting that SNAP-25 is integral to the normal function of these pathways.
Amphetamine dramatically reduced the locomotor activity of coloboma mice, similar to the response to psychostimulants in hyperkinetic children. In contrast, methylphenidate, another indirect acting dopamine agonist, increased the coloboma locomotor activity in a dose-dependent manner in parallel with their control littermates. The contrasting behavioral responses to the indirect acting dopamine agonists amphetamine and methylphenidate in coloboma mice likely reflect an abnormality intrinsic to presynaptic function as opposed to a more general systemic abnormality resulting from misregulation of the pathways governing locomotor activity. In normal mice, both amphetamine and methylphenidate increase synaptic catecholamine concentrations, resulting in locomotor hyperactivity through complex motor feedback loops including corticostriate, nigrostriatal, and striatepallido-thalamic loops. If one or all of these pathways were disrupted in coloboma mice, an increase in synaptic dopamine caused by either methylphenidate or amphetamine should result in a comparable and parallel behavioral response. Instead, we have observed opposite responses to these two drugs, suggesting that the differences in the drugs' mechanism of action are responsible for the contrasting behavioral responses to amphetamine and methylphenidate.
Because both methylphenidate and amphetamine act at the presynaptic terminal, it is likely that abnormalities in presynaptic mechanisms that involve SNAP-25 are responsible for the opposing effects of the drugs. Although methylphenidate and amphetamine produce behavioral activation by increasing the synaptic concentration of dopamine, the mechanisms of action of these two drugs are dissimilar. Psychostimulants have been categorized on the basis of whether the response is attenuated by pretreatment with reserpine (ScheelKruger, 1971; McMillen, 1983) a drug that disrupts vesicular release by depleting vesicular stores of catecholamines. The action of amphetamine and amphetamine-like compounds is not inhibited by reserpine pretreatment and is therefore thought to increase synaptic dopamine levels independent of vesicular release. In fact, amphetamine itself appears to disrupt vesicular stores of dopamine and causes reversal of the dopamine transporter, resulting in the etIlux of dopamine via the transporter (Sulzer and Rayport, 1990; Sulzer et al., 1993 Sulzer et al., , 1995 . In contrast, the methylphenidate class of psychostimulants (methylphenidate, cocaine, and nomifensine) blocks reuptake (Scheel-Kruger, 1971; Butcher et al., 1991) and is inhibited by reserpine-induced vesicular depletion. In coloboma mice, methylphenidate produces classical psychostimulant effects, suggesting that reuptake mechanisms and postsynaptic responses are functional. The paradoxical effects produced by amphetamine are more difficult to interpret. That coloboma mice respond to low doses of amphetamine with a decrease in locomotor activity suggests that amphetamine may actually be reducing synaptic dopamine concentrations. In fact, it has been demonstrated recently that in rats, the response to low-dose amphetamine is significantly blunted after disruption of vesicular release by reserpine whereas vesicular disruption has little effect on the response to moderate doses of amphetamine (Florin et al., 1995) similar to the effect observed in coloboma mice in which SNAP-25, a protein involved in vesicular release, is disrupted. As yet, the mechanism underlying this effect is unknown. Having defined the abnormal molecular condition that can give rise to the paradoxical response to amphetamine, the coloboma mouse model of hyperactivity will clearly be useful in defining this unusual drug response.
Interestingly, a dichotomy in the response to amphetamine and methylphenidate, similar to the coloboma mouse response, has also been observed in a subgroup of ADHD-affected children. Both methylphenidate and amphetamine are efficacious in the majority of children diagnosed with ADHD. However, a subset of children responds with an amelioration of symptoms only to amphetamine or methylphenidate whereby -20% are amphetamine-only responders and -20% respond only to methylphenidate (Arnold et al., 1978; Elia et al., 1991) . From the double-blind crossover study of Arnold et al. (1978) it was not clear whether the alternative drug would produce overt hyperactivity in these children, similar to the effects of methylphenidate in coloboma mice. The heterogeneity in effective treatment strategies for ADHD-affected children likely reflects the multifactorial nature of this disorder whereby several genes or environmental influences can produce phenotypically similar syndromes. The coloboma mouse model of hyperactivity parallels ADHD amphetamine-only responders and may provide, with other animal models of hyperactivity, a starting point for biologically categorizing different forms of ADHD to enable more effective individualized treatment strategies.
It has been suggested that the sedative effect of psychostimulants in hyperactive children and animals is not truly "paradoxical" but is a rate-dependent phenomenon based on the dose-response curves for psychostimulants (Sahakian and Robbins, 1977; Glick and Milloy, 1973) . The dose-response effect of amphetamine and methylphenidate on locomotor activity is an inverted U-shaped function with low-dose psychostimulant producing an increase in locomotor activity and high doses reducing locomotor activity concomitant with an increase in highly repetitive behaviors (stereotypy), thereby "focusing attention." The rate-dependent hypothesis states that the high baseline activity in drug-naive hyperactive children essentially places them at the highest point in this U-shaped function. Therefore, treatment of hyperactive children with amphetamine, at doses that would induce hyperactivity in less active individuals, results in a decrease in locomotor activity and increased stereotyped behavior. However, our results argue against rate dependency as an explanation for the paradoxical effects of psychostimulants in ADHD. First, both methylphenidate and amphetamine produce similar U-shaped functions. Rate dependency predicts that both methylphenidate and amphetamine should reduce the locomotor activity exhibited by coloboma mice. Instead, a clear increment (up to an apparent ceiling) in coloboma mouse locomotor activity was observed in response to methylphenidate. Importantly, this response occurred in parallel with wild-type mice, suggesting that coloboma mice started at the same point in the function, but with an overall higher baseline level. Next, although low dose amphetamine clearly decreased the locomotor activity of hyperactive coloboma mice, the suppression of hyperkinesis did not result from a shift from locomotor activity to stereotypy; that is, sedation was independent of stereotypy and the normal U-shaped function in wild-type mice. Thus, the effect of amphetamine in these mice is truly paradoxical. Taken together, these results suggest that locomotor activity and stereotypy are not components of a behavioral continuum as suggested by the rate dependency hypothesis, but separate distinct and likely competing behaviors induced by psychostimulants.
Because amphetamine and methylphenidate act at the presynaptic terminal, the aberrant behavioral response exhibited by coloboma mice suggests that defects in presynaptic function, resulting from SNAP-25 deficiencies, are responsible for abnormalities in the regulation of locomotor activity in coloboma mice. In fact, correction of the amphetamine response in coloboma mice with the Snap transgene supports this hypothesis. Thus, in addition to its central role in the expression of hyperactivity, SNAP-25 influences the behavioral response to indirect dopamine agonists. The availability of an animal model with a defined genetic defect provides a means to explore the biochemical interactions that not only mediate psychostimulant response, but may also help identify neural pathways involved in hyperactivity and facilitate the discovery of novel therapeutics for the treatment of hyperactivity syndromes.
